Welcome to our dedicated page for Valneva SE American news (Ticker: VALN), a resource for investors and traders seeking the latest updates and insights on Valneva SE American stock.
Valneva SE develops, manufactures and commercializes prophylactic vaccines for infectious diseases, with revenue from proprietary travel vaccines and a pipeline of vaccine candidates. News about VALN commonly covers clinical and regulatory developments for the Lyme disease vaccine candidate PF-07307405/LB6V, partnered with Pfizer, as well as Shigella, chikungunya and other infectious-disease programs.
Company updates also include commercial partnerships, licensing arrangements such as vaccine-antigen technology agreements, manufacturing and supply collaborations, marketing and distribution relationships, operating results, and capital actions tied to Valneva's vaccine portfolio and public-company status on Nasdaq and Euronext Paris.
Pfizer reported third-quarter 2021 revenues of $24.1 billion, a 134% increase year-over-year, driven by the success of the Comirnaty vaccine, which contributed $13 billion. Excluding Comirnaty, revenues still grew 7% to $11.1 billion. The reported diluted EPS was $1.42, with adjusted EPS at $1.34. Pfizer raised its full-year revenue guidance to $81-82 billion and adjusted EPS to $4.13-4.18. The company anticipates around $36 billion in revenue from Comirnaty for 2021, with plans to deliver 2.3 billion doses globally.